fibrinolysis

6-Aminocaproic acid (EACA) is an antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.

UK-396082 is a thrombin-activated fibrinolysis inhibitor (TAFI) that inhibits Carboxypeptidase B. It is used in the study of thrombosis, atherosclerosis, cancer, and fibrotic conditions.

Tranexamic acid (Amstat) is an Antifibrinolytic Agent. The physiologic effect of tranexamic acid is by means of Decreased Fibrinolysis.

DS-1040 Tosylate is a thrombin-activated fibrinolysis inhibitor (TAFIa) inhibitor, also a fibrinolysis enhancer, inhibiting TAFIa and carboxypeptidase N, reducing fibrin clots in the lungs, useful in thromboembolic disease research.

SYN-UP is an inhibitor of fibrinolysis.

Alpha 2 Antiplasmin serves as the principal circulating inhibitor of plasmin. This compound plays a crucial role in regulating fibrinolysis within blood vessels.

BT-114143 is a plasminogen activator inhibitor with an IC50 of 8.42 μM. It is applicable in research related to hemorrhagic diseases caused by excessive fibrinolysis, including traumatic bleeding, severe menorrhagia, postpartum hemorrhage, and complications of hemophilia.

CDE-096 is a potent inhibitor of plasminogen activator inhibitor-1 that prevents PAI-1–mediated inactivation of tissue plasminogen activator and urokinase plasminogen activator with nanomolar potency, while maintaining activity against glycosylated and multispecies PAI-1, enabling translational research in fibrinolysis and thrombosis regulation.

SQ-24,798 is an inhibitor of the thrombin-activatable fibrinolysis and carboxypeptidase N (CPN).

SN50 TFA is a cell-permeable inhibitor of NF-κB and attenuates alveolar hypercoagulation and fibrinolysis inhibition in acute respiratory distress syndrome mice through inhibiting NF-κB p65 translocation. SN50 TFA can be used in studies about ARDS.

S62798 is a highly potent and selective compound that inhibits activated thrombin activatable fibrinolysis inhibitor (TAFIa) with an IC50 value of 6 mM.

Streptokinase is a bacterial-derived protein that functions as a plasminogen activator, extensively utilized in research on blood coagulation and fibrinolysis, and its experimental applications include studying thrombolytic mechanisms, vascular biology, and reperfusion processes following coronary artery occlusion in cardiovascular disease models.

PSI-112 is a fibrinolysis inhibitor.

SAR-104772 is a novel inhibitor of TAFIa (activated thrombin-activatable fibrinolysis inhibitor).

AZD6564 is a fibrinolysis inhibitor which acts via interference of a protein-protein interaction.

5-trans-Prostaglandin E2 accelerates fibrinolysis by enhancing plasminogen activation mediated by tissue-type plasminogen activator. It also inhibits platelet aggregation in human PRP.

6-Aminocaproic acid hydrochloride, a monoamino carboxylic acid derivative, is a potent, orally active antifibrinolytic agent that inhibits plasmin and plasminogen. It competitively binds to lysine residues on plasminogen, preventing clot lysis by inhibiting plasmin formation and reducing fibrinolysis. This compound is utilized in researching bleeding disorders.

Glycylglycylcysteine is an inhibitor of Thrombin Activatable Fibrinolysis Inhibitor (TAFI), exhibiting a K_i value of 0.99 µM and an IC_50 of 9.4 µM in TAFI substrate assays. TAFI, a basic carboxypeptidase, hinders fibrinolysis by cleaving C-terminal lysine residues on partially degraded fibrin [1].

Drotrecogin alfa (activated) (DrotAA), a recombinant human activated protein C (APC), mitigates smoke-induced elevations in pulmonary microvascular permeability and proinflammatory cytokine IL-1β levels in rats. It also inhibits coagulation and inflammation while enhancing fibrinolysis. Drotrecogin alfa (activated) is applicable in severe sepsis research [1] [2].

Anti-SERPINE1 Antibody is a humanized monoclonal antibody targeting Serpin Family E Member 1 (SERPINE1/PAI-1). SERPINE1, also known as Plasminogen Activator Inhibitor-1 (PAI-1), is the primary physiological inhibitor of tissue-type (tPA) and urokinase-type (uPA) plasminogen activators, playing a critical role in regulating fibrinolysis, cell migration, and tissue remodeling. Elevated PAI-1 levels are associated with thrombosis, fibrosis, metabolic syndrome, and tumor progression (including immune evasion and metastasis). Anti-SERPINE1 Antibody specifically binds to PAI-1, neutralizing its inhibitory activity and restoring tPA/uPA-mediated plasmin generation to promote fibrinolysis and reduce extracellular matrix deposition. Additionally, the antibody blocks PAI-1-mediated upregulation of PD-L1, thereby enhancing anti-tumor immune responses in the tumor microenvironment, and possesses potential anti-senescence properties.

6-Aminocaproic acid-d6 is the deuterated form of 6-Aminocaproic acid (EACA), a monoamino carboxylic acid. This compound acts as an effective and orally active inhibitor of plasmin and plasminogen. It serves as a potent antifibrinolytic agent by competitively binding to lysine residues on plasminogen, preventing clot dissolution, inhibiting plasmin formation, and reducing fibrinolysis. Additionally, 6-Aminocaproic acid is utilized in the study of hemorrhagic disorders.

Tranexamic Acid-13C2-15N is the 13C and 15N labeled compound of Tranexamic Acid. Tranexamic Acid has a CAS number of 1197-18-8. Tranexamic acid is an Antifibrinolytic Agent. The physiologic effect of tranexamic acid is by means of Decreased Fibrinolysis.

Plactin B is a cyclic pentapeptide compound that facilitates the dissolution of fibrinolysis proteins.

Human D-dimer protein serves as an excellent biomarker for thrombosis. It is the final product of fibrinolysis.